Darlene Dobkowski, MA

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.

A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and side effect management, among others.

A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.

Former U.S. President Jimmy Carter called attention to the immunotherapy drug Keytruda, which was used to successfully treat his cancer.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development.

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.

A health care professional talks about the importance of a supportive care team, especially since every patient with MPNs presents differently.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.